Does insulin glargine increase the risk of cancer compared with other basal insulins? A French nationwide cohort study based on national administrative databases

Diabetes Care

Volumn 36, Issue 2, 2013, Pages 294-301

  Fagot, Jean Paul ^a   Blotière, Pierre Olivier ^a   Ricordeau, Philippe ^a   Weill, Alain ^a   Alla, François ^a   Allemand, Hubert ^a  

^a National Health Insurance   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN DETEMIR; INSULIN GLARGINE; LONG ACTING DRUG; METFORMIN; PIOGLITAZONE; PROSTATE SPECIFIC ANTIGEN; ROSIGLITAZONE; SOMATOMEDIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONFOUNDING VARIABLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EXPOSURE; DRUG METABOLISM; ETHNIC GROUP; FEMALE; FRANCE; FRENCH LANGUAGE; HAZARD RATIO; HEAD AND NECK CANCER; HEALTH INSURANCE; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MAMMOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PROSTATE CANCER;

ADULT; AGED; DATABASES, FACTUAL; FEMALE; FRANCE; HUMANS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; NEOPLASMS;

EID: 84873828993     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0506     Document Type: Article

References (31)

1. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52:1732-1744
2. Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52: 1755-1765
3. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52: 1766-1777
4. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Dia-betologia 2009;52:1745-1754
5. Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005
6. Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R. Glargine blood biotransformation: in vitro appraisal with human insulin im-munoassay. Diabetes Metab 2007;33:205-212
7. Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 2009;374:511-513
8. Hernández-Díaz S, Adami HO. Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 2010;53:802-808
9. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52:2499-2506
10. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 2010;58:286-290
11. Païta M, Weill A. Patients with long term disease on 31 December 2008 [Internet]. Available from http://www.ameli.fr/fileadmin/user-upload/ documents/27-ALD-2008. pdf. Accessed 12 August 2011 [in French]
12. Website of Technical Hospitalization Information Agency (ATIH) [Internet]. Available from http://www.atih.sante.fr. Accessed 12 August 2011 [in French]
13. Tuppin P, Neumann A, Marijon E, et al. Implantation and patient profiles for pacemakers and cardioverter-defibrillators in France (2008-2009). Arch Cardiovasc Dis 2011;104:332-342
14. Weill A, Païta M, Tuppin P, et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010;19: 1256-1262
15. Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 2011;29:3610-3616
16. Bélot A, Velten M, Grosclaude P, et al. Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2005 [Internet]. Saint-Maurice, France, Institut de veille sanitaire, December 2008. Available at http://www.invs.sante.fr/publications/2009/estimation-cancer-1980- 2005/estimation-cancer-1980-2005.pdf. Accessed 12 August 2011 [in French]
17. Remontet L, Mitton N, Couris CM, et al. Is it possible to estimate the incidence of breast cancer from medico-administrative databases? Eur J Epidemiol 2008;23:681-688
18. Mitton N, Colonna M, Trombert B, et al. A suitable approach to estimate cancer incidence in area without cancer registry. J Cancer Epidemiol 2011;2011: l418968
19. Van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012;55:654-665
20. Chang CH, Toh S, Lin JW, et al. Cancer risk associated with insulin glargine among adult type 2 diabetes patientsda nationwide cohort study. PLoS ONE 2011;6: e21368
21. Blin P, Lassalle R, Dureau-Pournin C, et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012;55: 644-653
22. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997;145:72-80
23. The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med 11 June 2012 [Epub ahead of print]
24. Teng JA, Hou RL, Li DL, Yang RP, Qin J. Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation. Horm Metab Res 2011;43: 519-523
25. Ljung R, Talbäck M, Haglund B, Jonasson JM, Gudbjörnsdò ttir S, Steineck G. Insulin glargine use and short-term incidence of malignanciesa three-year population-based observation. Acta Oncol 2011;50:685-693
26. Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011;54:2254-2262
27. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012;55: 51-62
28. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011;34:1965-1971
29. Lind M, Fahlén M, Eliasson B, Odén A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes 2012;6:53-59
30. FDA Drug Safety Communication. Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer [Internet]. Available from http://www.fda.gov/Drugs/DrugSafety/ucm239376.htm. Accessed 21 October 2011
31. European Medicines Agency update on safety of insulin glarginedupdate [Internet]. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/ news-and-events/news/2009/11/news-detail-000066.jsp&murl=menus/ news-and-events/news-and-events.jsp&mid=WC0b01ac058004d5c1. Accessed 21 October 2011